Research
Hormonal
Cholecystokinin (CCK) attenuates reward-related signaling and motivation for food, acting as a satiety signal that can block the acquisition of conditioned place preference associated with rewarding stimuli.
Satiety hormones like CCK don't just turn off hunger; they can also reduce the reward value of food, making it less appealing.
ModerateSupportsMEDIUM confidence
Peripheral administration of CCK reduces operant responses for Noyes pellets in rats... Microinjections of CCK into the NAc attenuated VTA intracranial self-stimulation (ICSS)... suggesting that CCK attenuates reward signalling derived from the VTA.
Why this rating
Primarily based on rodent studies; less direct human clinical evidence for reward modulation compared to GLP-1.
Source
Gut peptide regulation of food intake - evidence for the modulation of hedonic feeding.
Orla Woodward et al. · Apollo (University of Cambridge) · 2021
DOI 10.17863/cam.74301
narrative_reviewCited 38×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Gut peptides (specifically GLP-1 and GIP) modulate hedonic feeding and reward-seeking behavior, extending beyond homeostatic satiety, which provides a mechanism for the significant weight loss observed with GLP-1/GIP receptor agonists.Good
- Ghrelin, the 'hunger hormone', directly stimulates reward pathways in the brain (VTA and NAc) to increase motivation and willingness to work for food, particularly palatable/high-fat foods.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →